Sugi Predict

Sugi Predict / Compounds / SCHEMBL1965621

SCHEMBL1965621

SCHEMBL1965621

CC(C)(C)OC(=O)C1CC(O)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 1/20 0.48
▸ CHRM1 P11229 1/20 0.48
▸ CHRM3 P20309 1/20 0.48
▸ HRH3 Q9Y5N1 1/20 0.40
▸ MAPK1 P28482 2/20 0.37
▸ BTK Q06187 1/20 0.36
▸ NR1H2 P55055 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ CHRNB2 P17787 2/20 0.32
▸ CHRNA4 P43681 2/20 0.32
▸ CHRNB4 P30926 1/20 0.32
▸ CHRNA3 P32297 1/20 0.32
▸ CHRNA7 P36544 1/20 0.32
▸ DGAT1 O75907 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ RECQL P46063 1/20 0.31
▸ USP2 O75604 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ NFKB1 P19838 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3958434 1.00 CHRM2 (0.48) CHRM2CHRM1CHRM3HRH3MAPK1
SCHEMBL2342365 1.00 CHRM2 (0.48) CHRM2CHRM1CHRM3HRH3MAPK1
SCHEMBL18347541 0.90 CHRM2 (0.42) CHRM2CHRM1CHRM3HRH3MAPK1
SCHEMBL1298062 0.88 HRH3 (0.43) CHRM2CHRM1CHRM3HRH3MAPK1
SCHEMBL26999357 0.85 CHRM2 (0.44) CHRM2CHRM1CHRM3HRH3MAPK1
SCHEMBL1139458 0.85 CHRM2 (0.44) CHRM2CHRM1CHRM3HRH3MAPK1
SCHEMBL9651542 0.85 CHRM2 (0.44) CHRM2CHRM1CHRM3HRH3MAPK1
SCHEMBL11920529 0.82 BTK (0.45) CHRM2CHRM1CHRM3HRH3MAPK1
SCHEMBL21597046 0.82 CHRNB2 (0.39) CHRM2CHRM1CHRM3HRH3MAPK1
SCHEMBL19465321 0.82 BTK (0.45) CHRM2CHRM1CHRM3HRH3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090317-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 — — WO disclosed
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
EP-4665720-A2 ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE Bristol-Myers Squibb Company (US) 2025-12-24 — — EP disclosed
EP-4223750-B1 NITROGEN-CONTAINING BICYCLIC COMPOUNDS WHICH CONTAIN PYRIMIDINE AS INTERLEUKIN 1 RECEPTOR-ASSOCIATED KINASE 4 (IRAK-4) INHIBITORS TO BE USED IN THE TREATMENT OF INFLAMMATORY OR AUTOIMMUNE DISEASES ASAHI KASEI PHARMA CORP (JP) 2025-06-25 — — EP disclosed
WO-2025106362-A1 RIPK1 INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2025-05-22 — — WO disclosed
CN-118955473-A Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway 紐力克斯治疗公司 2024-11-15 — — CN disclosed
US-12139478-B2 Compounds, compositions and methods DENALI THERAPEUTICS INC. (US) 2024-11-12 — — US disclosed
WO-2024173832-A2 ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-22 — — WO disclosed
CN-113412259-B Difunctional compounds for degrading BTK via the ubiquitin proteasome pathway 紐力克斯治疗公司 2024-07-16 — — CN disclosed
CN-118239938-A Compounds, compositions, and methods 戴纳立制药公司 2024-06-25 — — CN disclosed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 — — US disclosed
US-7507742-B2 Spirocyclic derivatives PFIZER INC. (US) 2009-03-24 — — US disclosed
CN-100400041-C Diaminothiazoles useful as selective inhibitors of CDK4 HOFFMANN LA ROCHE (CH) 2008-07-09 — — CN disclosed
US-20070129388-A1 Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid PFIZER, INC. 2007-06-07 — — US disclosed
EP-1507530-B1 DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS HOFFMANN LA ROCHE (CH) 2005-11-02 — — EP disclosed
CN-1652780-A Diaminothiazoles used as CDK4 inhibitors HOFFMANN LA ROCHE (CH) 2005-08-10 — — CN disclosed
EP-1507530-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-02-23 — — EP disclosed
US-6818663-B2 AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS HOFFMANN-LA ROCHES 2004-11-16 — — US disclosed
US-20040006058-A1 DIAMINOTHIAZOLES CHU XIN-JIE (US) 2004-01-08 — — US disclosed
WO-2003097048-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12139478-B2 Compounds, compositions and methods EIF4EBP1, EIF4B, EIF4E CHRM2 4877/4885CHRM1 4875/4885CHRM3 4871/4885
US-20070129388-A1 Phosphodiesterases inhibitors specially PDE7; To treat pain, especially neuropathic pain; superior pharmacokinetics; 3-[(8'-Chloro-2'-oxo-2',3'-dihydro-1'H-spiro[cyclohexane-1,4'-quinazolin]-5'-yl)oxy]cyclobutanecarboxylic acid PDE7A, PDE7B, PDE3A CHRM2 732/4885CHRM1 371/4885CHRM3 798/4885
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS EIF2B1, EIF4EBP1, EIF2B3 CHRM2 4802/4885CHRM1 4757/4885CHRM3 4821/4885
US-20040006058-A1 DIAMINOTHIAZOLES CDK4, CDK1, CDK2 CHRM2 3737/4885CHRM1 3288/4885CHRM3 4006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.